Post-Authorization Long-Term Safety Study of LUTATHERA (NCT03691064)

🧪 Interventions in This Study

• LUTATHERA (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (20 Sites)

• Banner MD Anderson Cancer Center — Phoenix, Arizona
• The Ohio State University Wexner Medical Center — Portland, Ohio
• Oregon Health & Sciences University Hospital — Portland, Oregon
• Virginia Mason in Seattle — Seattle, Washington
• Novartis Investigative site — Clichy,
• Novartis Investigative site — Lyon,
• Novartis Investigative site — Villejuif,
• Novartis Investigative site — Coimbra, Coimbra District
• Novartis Investigative site — Santiago de Compostela, La Corunya
• Novartis Investigative site — Majadahonda, Madrid
• Novartis Investigative site — Birmingham,
• Novartis Investigative site — Cambridge,
• Novartis Investigative site — Glasgow,
• Novartis Investigative site — Liverpool,
• Novartis Investigative site — London,
• Novartis Investigative site — London,
• Novartis Investigative site — London,
• Novartis Investigative site — London,
• Novartis Investigative site — Manchester,
• Novartis Investigative site — Sheffield,

📞 Contact the Study Coordinator

Phone: (877) 632-6789

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Neuroendocrine Tumors

• Targeted Alpha-emitter Therapy of PRRT Naïve and Previous PRRT Neuroendocrine Tumor Patients — Denver, Colorado
• Lu-DOTATATE Treatment in Patients With 68Ga-DOTATATE Somatostatin Receptor Positive Neuroendocrine Tumors — Hamilton, Ontario
• A Safety Study of 212Pb-VMT-alpha-NET in Patients With Neuroendocrine Tumors — Iowa City, Iowa
• Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients — Gilbert, Arizona
• Lesion-to-lesion Comparison of 68Ga-HA-DOTATATE, 18F-DOPA, and 18F-FDG PET/CT in the Evaluation of Metastatic Neuroendocrine Tumors — Edmonton, Alberta

Explore by condition: All Neuroendocrine Tumors clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.